JT
BCRX icon

Jump Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jump Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-16,200
Closed -$132K – 351
2019
Q1 		$132K Buy
+16,200
New +$139K 0.04% 455
2018
Q4 		– Sell
-14,500
Closed -$111K – 242
2018
Q3 		$111K Buy
+14,500
New +$97.4K 0.01% 369

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Jump Trading's BCRX Position: Q2 2019 in Review

Jump Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 16,200 shares — an estimated $132K sold.

Jump Trading first reported a position in BCRX in Q3 2018 and held it in 2 quarters. The position peaked at $132K in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

  • Jump Trading reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Jump Trading sold 16,200 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $132K.
  • Jump Trading first reported a position in BioCryst Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Jump Trading's BioCryst Pharmaceuticals position peaked at $132K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Jump Trading's 13F filing for Q2 2019, filed 14 Aug 2019.